Eli Lilly (LLY) USD (CDI)

Sell:$826.08Buy:$826.80$16.57 (2.04%)

Prices delayed by at least 15 minutes
Sell:$826.08
Buy:$826.80
Change:$16.57 (2.04%)
Deal now
Prices delayed by at least 15 minutes
Sell:$826.08
Buy:$826.80
Change:$16.57 (2.04%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).

Key people

David A. Ricks
Chairman of the Board, President, Chief Executive Officer
Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Daniel M. Skovronsky
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Alonzo Weems
Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer
Anat Hakim
Executive Vice President, General Counsel, Secretary
Eric Dozier
Executive Vice President - Human Resources and Diversity
Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Patrik Jonsson
Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA
Johna L. Norton
Executive Vice President - Global Quality
Juan Ricardo Luciano
Lead Independent Director
Raul Alvarez
Independent Director
Katherine Baicker
Independent Director
J. Erik Fyrwald
Independent Director
Mary Lynne Hedley
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US5324571083
  • Market cap
    $769.35bn
  • Employees
    43,000
  • Shares in issue
    949.68m
  • Exchange
    New York Stock Exchange
  • Index
    S&P 500, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.